Published Chronic Fatigue Syndrome Drug News
ULTRAM ER (Tramadol HCl) Extended-Release Tablets Now Available In USA for Chronic Pain
A new prescription option — ULTRAM ER — is now available to the more than 50 million Americans who suffer from moderate to moderately severe chronic pain.
First Randomized Double Blind Clinical Trial on Swiss Medica’s O24 Fibromyalgia Published in Medical Journal
Swiss Medica is pleased to announce that the randomized double blind clinical trial using O24 Fibromyalgia on patients suffering from Fibromyalgia has been published in the Practical Pain Management Journal,
Research: Commonly Used Antidepressants May Also Affect Human Immune System (CFS and FM Related News)
Drugs that treat depression by manipulating the neurotransmitter serotonin in the brain may also affect the user’s immune system in ways that are not yet understood, say scientists from Georgetown University Medical Center and a Canadian research institute.
Forest Laboratories, Inc. and Cypress Bioscience, Inc. to Commence Third Milnacipran Phase III Trial
Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) today announced that they will initiate a third randomized, double-blind, placebo-controlled pivotal Phase III study evaluating milnacipran as a treatment for fibromyalgia (FMS) in the first quarter of 2006.
Pramipexole Delivered Sustained Efficacy in Clinical Trial of Patients with Restless Legs Syndrome
Two large, randomized, placebo-controlled studies presented at the inaugural conference of the World Association of Sleep Medicine in October, demonstrate that pramipexole delivered both short-term and sustained efficacy in patients suffering from Restless Legs Syndrome enrolled in these trials.
Research: Narcolepsy Drug Relieves Pain and Improves Sleep in Fibromyalgia Patients
The National Fibromyalgia Association (NFA) announced that a recent study on the narcolepsy drug Xyrem® (sodium oxybate) showed the drug significantly reduces pain and improves sleep in people with fibromyalgia.
Study Shows People Unaware of Harmful Effects of Painkillers
Findings of a new study signify the need for better patient education on the complications of misusing painkillers.
Report: Reformulated Drugs Will Drive Market for Treatment of Chronic Pain
The new Pharmacor report entitled Chronic Pain: Key Populations, Market Size, and the Driving Force of Drug Reformulations finds that the antidepressant and antiepileptic drug sectors will also experience significant growth over the next decade as a result of new approvals — and thus more widespread use — for chronic pain conditions.
Symptom Improvements with Parkinson’s Drug Mirapex Found in Fibromyalgia Trial
The dopamine agonist pramipexole, (Mirapex) currently indicated by the FDA for treatment of Parkinson’s disease, provides a high response rate of overall fibromyalgia (FM) symptom improvements, as well as promoting significant weight loss, according to data to be presented in a late breaking abstract on Thursday, October 21, at the American College of Rheumatology Annual Scientific Meeting.
Newport Pharmaceuticals Ltd. Announces Update on Co-Development Program For Isoprinosine For Chronic Fatigue Syndrome
Newport Pharmaceuticals Ltd (NPL), a privately owned company focusing on immunological disorders, commented today on its phase II clinical development program for lead product Isoprinosine(r) (Inosine Acetoben Dimepranol) (IAD) for the treatment of chronic fatigue syndrome (CFS) in the United States.